What to look forward to in GU cancers at ESMO 2024

Описание к видео What to look forward to in GU cancers at ESMO 2024

Aristotelis Bamias, MD, PhD, University of Athens, Athens, Greece, shares his top picks in genitourinary cancers at ESMO 2024, including findings from the NIAGARA study (NCT03732677) of neoadjuvant immunotherapy, as well as updates from the use of belzutifan in kidney cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке

Похожие видео